

HCV Drug Market Storm Brewing; CBCD Reviews a Report

Last week, the U.S. Food and Drug Administration approved a new drug, Viekira Pak, as a cure for Hep C. (1)

ROCHESTER, NEW YORK, UNITED STATES, January 2, 2015
/EINPresswire.com/ --

“Infected with the hepatitis C virus (HCV)? The CBCD recommends taking [Novirin](#) or [Gene-Eden-VIR](#).” - Greg Bennett, CBCD

The FDA has approved a new drug against the hepatitis C virus (HCV). The drug's name is Viekira Pak, and is made by AbbVie (ABBV). Viekira Pak is a combination drug made from, “(ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis.” (See the FDA, from December 19, 2014) (2) The price of Viekira Pak is “about 12 percent cheaper than its rival from Gilead Sciences Inc. (GILD), setting the stage for fierce competition for patients of the liver virus.” (See Bloomberg.com, from December 20, 2014) (3) “With new competition, the price of (Sovaldi) is likely to see decreases. The country's largest pharmacy benefit manager, Express Scripts, is already lining up behind the Viekira Pak.” (1)

Even with the possibility that competition will drive the cost of HCV drugs down, Forbes noted that these high costs “are hitting Medicaid health insurance programs for poor Americans particularly hard because the population of patients in need of Hepatitis C treatments tends to have low incomes and wouldn't be able to afford the drug otherwise. Medicaid is funded by state and federal tax dollars and administered by state governments.” (4)



“For those infected with the latent HCV, we recommend Novirin or Gene-Eden-VIR. The formula of these natural HCV

post-marketing clinical study that followed FDA guidelines.” – Greg Bennett, CBCD

Click to learn more about [HCV symptoms](#).

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against the hepatitis C virus, and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with HCV ... reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (5) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (5)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites.

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

According to Forbes, “It’s unclear exactly how Medicaid programs will deal with ... the coming wave of Hepatitis C drugs also expected to get Food and Drug Administration approval from Abbvie (ABBV), Bristol-Myers (BMS) and Merck (MRK).” (4)

The pharmaceutical companies don’t appear to be concerned about losing business due to the high costs of their HCV drugs. “Abbvie plans to focus on Viekira Pak’s high cure rate, including in hard-to-treat patients, such as those who also have HIV, instead of the higher number of pills it will require daily.” (1) Michael Severino said “We believe the performance of our product speaks for itself.” (1) Mr. Severino is the executive vice president of research and development at Abbvie. “In six clinical trials testing Viekira Pak, 91 percent to 100 percent of patients, including those considered difficult to treat, were cured. Common side effects include tiredness, itching, nausea and trouble sleeping.” (1)

What other treatments are currently available against the HCV virus?

Until recently, “the combination of a pegylated interferon (IFN)- α and ribavirin (was) the standard treatment for chronic HCV infections. This combination is effective in about 80% of the individuals infected with the HCV genotype 2 or 3, and in about 40% – 50% in those infected with genotype 1 or 4. Lately, two new drugs were approved, telaprevir and boceprevir, with better results. However, the combinations of pegylated interferon (IFN)- α and ribavirin and telaprevir or boceprevir are associated with additional side effects, increased costs, and more complex treatment strategies.” (5) There are also newly approved drugs including Sovaldi, Harvoni, and Viekira Pak.

“Unlike these costly drugs, Novirin and Gene-Eden-VIR are natural remedies designed to target the latent HCV.” - Greg Bennett, CBCD

References:

(1) Arnold, E. "A new drug challenges pricey Hep C cure." Bizjournals.com - Published December 22,

2014.

<http://www.bizjournals.com/memphis/news/2014/12/22/a-new-drug-challenges-pricey-hep-c-cure.html>

(2) FDA.gov - FDA approves Viekira Pak to treat hepatitis C. Published December 19, 2014.

<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm>

(3) Edney, A., Chen, C. "AbbVie Prices Hepatitis C Drug 12% Below Gilead Rival" - Bloomberg.com. Published December 20, 2014.

<http://www.bloomberg.com/news/2014-12-19/abbvie-wins-u-s-approval-to-sell-new-hep-c-competitor.html>

(4) Forbes.com - As Pricey Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles. Published October 10, 2014.

<http://www.forbes.com/sites/brucejapsen/2014/10/10/as-hepatitis-pill-harvoni-joins-sovaldi-states-erect-medicaid-hurdles/>

(5) Gene-Eden-VIR is Antiviral: Results of a Post marketing clinical study. Published in September 2013. scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VE44nyKUf90

Hanan Polansky
Lilac Corp.
5852509999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.



